Table 1: Patient and treatment characteristics of the 43 patients.

FactorsCharacteristicNumber of casesPercentage

GenderMale3888.4%
Female511.6%
Age (years old)Median56
Range35–78
NSCLC2762.8%
HistologySCLC1534.9%
Metastases12.3%
I-II27.4%
Stage of NSCLC
( = 27)
IIIA518.5%
IIIB1555.6%
IV518.5%
Stage of SCLC
( = 15)
Limited stage15100%
T11023.8%
T status*T2716.7%
T3716.7%
T41842.8%
N0-1511.9%
N status*N21638.1%
N32150%
Left upper lobe1636.4%
Left lower lobe12.3%
Tumor locationRight upper lobe1738.6%
Right middle lobe49.1%
Right lower lobe613.6%
GTV volume
(cm3)
Median45
Range0.5–454
Tumor attachment statusSolitary tumor1431.8%
Attached tumor3068.2%
Median62
Treatment dose of NSCLC (Gy) ( = 27)Range54–70
<60622.2%
60–651348.1%
66–70829.6%
Treatment dose of SCLC ( = 15)4515100%
Concurrent
chemoradiotherapy*
NSCLC2488.9%
SCLC15100%

One nasopharyngeal carcinoma patient with isolated lung metastases was not included in the T or N status calculation.
One NSCLC patient had two lung lesions.
Two early patients received radiation alone. One locally advanced patient canceled chemotherapy for active tuberculosis.
NSCLC: nonsmall cell lung cancer; SCLC: small cell lung cancer; GTV: gross tumor volume.